Graves病^(131)I治疗的研究进展  

Research Progress in ^(131)I Treatment for the Graves Disease

作　　者：王朋[1,2] 代文莉[1,2] 胡涛[1,2] 严凯[1,2] 胡伟[1,2] 崔邦平[1,2] 

机构地区：[1]三峡大学第一临床医学院 [2]宜昌市中心人民医院核医学科宜昌市核医学分子影像重点实验室,湖北宜昌443003

出　　处：《医学综述》2015年第12期2194-2196,共3页Medical Recapitulate

基　　金：宜昌市科学研究与开发项目(A13301-12)

摘　　要：Graves病(GD)是由多种原因引起的甲状腺激素分泌过多,导致机体代谢异常增高、功能紊乱,甚至组织器官损害的综合征。目前,GD有内科药物治疗、外科手术治疗、核医学131I治疗三种成熟的治疗方法。核医学131I治疗以其独特优势已经被越来越多的患者和临床医师所接受,成为最常用的治疗方法之一。熟悉治疗原理、正确选择适应证、合理制订给药剂量、预防可能的不良结局,是GD131I治疗的基础。Graves disease（ GD） is a common endocrine disease,which accounts for the majority of the hyperthyroidism. GD is a syndrome caused by a variety of reasons of thyroid hormone hypersecretion,leading to syndromes of abnormal metabolic increase,functional disorders of the body,and even organs injury. At present,there are three matured treatments for the GD： internal medicine,surgery and nuclear medicine131 I treatment. And nuclear medicine131 I treatment has become one of the most commonly used methods due to its unique advantages. Understanding the principle of treatment,correct selection of indications,reasonable calculation of the dose and prevention of adverse outcomes are the foundation of the GD131 I treatment.

关 键 词：甲状腺功能亢进 GRAVES病 ^131I 甲状腺功能减退 

分 类 号：R817.5[医药卫生—影像医学与核医学]